Current Report · Items 8.01 · 8-K
Vaxart, Inc
Other Events
Item 8.01 Other Events. Reorganization of Committees of the Board of Directors On July 27, 2026, upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. (the “Board”) approved the reorganization of its Nominating and Governance Committee and the Compensation Committee, and the appointments of Kevin P.…
Company context
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.